Arcturus Therapeutics

Arcturus has more than $200 million in liquidity, giving it a funding runway into 2028 to support development of its programs. The company expects a Q4 2024 decision on advancing ARCT-032 (inhaled mRNA for cystic fibrosis) into phase III and anticipates data and regulatory guidance for ARCT-810 (OTC deficiency) before Sept. 30, 2024. The vaccine business, including KOSTAIVE (approved in 32 countries), has been returned to 100% strategic control and is intended to help fund the therapeutics pipeline. Arcturus is evaluating partnerships and has outlined a possible $40 million support from Thermo Fisher tied to a phase III decision. » Altro su de.investing.com

Arcturus reported an adjusted loss of $0.84 per share in Q2 versus a consensus expectation of $1.05, beating estimates by 20%. Revenue fell to $2.96 million, a decline of 89.4% year‑on‑year after the end of the collaboration with CSL Seqirus. Cash and equivalents amounted to $191.5 million, securing a liquidity runway of more than 2.5 years. The company cut R&D spending, is advancing cystic fibrosis (ARCT‑032) and OTCD (ARCT‑810) programs, and expects Phase II/III decisions and data in the second half of 2026. » Altro su de.investing.com

Arcturus Therapeutics wins Thermo Fisher Scientific as a strategic partner for the phase-3 development and potential commercialization of mRNA candidate ARCT-032. Analysts highlight progress with ARCT-810 as an important proof of concept for liver-specific diseases. BTIG affirms a price target of $23, and Freedom Broker rates the stock buy with a $27 price target. Experts see a low short-term dilution risk for shareholders. » Altro su finanzen.net